Physician profile
Hayder M Saeed
NPI 1851619118
$126,885.25
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,602 · 2020: $5,708 · 2021: $12K · 2022: $37K · 2023: $25K · 2024: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Consulting Fee: $28K · Food and Beverage: $1,141 · Travel and Lodging: $859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,712.05 |
| Consulting Fee | $27,924.31 |
| Food and Beverage | $1,141.44 |
| Travel and Lodging | $858.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acrotech Biopharma INC. | $38,312.89 | 2022-2024 | Beleodaq |
| Seagen INC. | $27,374.88 | 2019-2023 | Adcetris |
| Pfizer INC. | $10,519.10 | 2024 | |
| Epizyme, INC. | $9,996.62 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $8,766.17 | 2022 | |
| Incyte Corporation | $6,959.50 | 2021-2024 | Monjuvi |
| Morphosys, US INC. | $5,117.38 | 2021-2022 | |
| Genzyme Corporation | $4,314.00 | 2020 | |
| Ipsen Bioscience INC. | $3,215.00 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $2,901.87 | 2022-2023 | Tazverik |
| Secura Bio, INC. | $2,571.00 | 2021 | |
| Tg Therapeutics, INC. | $2,025.00 | 2022 | |
| Abbvie INC. | $1,650.00 | 2024 | |
| Adc Therapeutics America, INC. | $1,400.00 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $319.69 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene, Ltd. | $300.00 | 2024 | Brukinsa |
| Genmab U.S., INC. | $215.18 | 2023 | Epkinly |
| Kyowa Kirin, INC. | $208.88 | 2022-2024 | Poteligeo |
| Beigene USA, INC. | $193.28 | 2023-2024 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $128.58 | 2022 | |
| Verastem, INC. | $121.24 | 2019 | |
| Eli Lilly and Company | $106.41 | 2023 | |
| Genentech USA, INC. | $93.44 | 2022 | |
| Janssen Research & Development, LLC | $56.54 | 2022 | |
| Sobi, INC | $18.60 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hayder Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.